OpenLB
Open Library of Bioscience
Advanced Search
CMAJ open
2018 Oct-Dec;6 (4): E678-E684.

Benzodiazepine receptor agonist dispensations in Alberta: a population-based descriptive study.

Daniala L Weir, Salim Samanani, Fizza Gilani, Ed Jess, Dean T Eurich
Author Information
  1. Daniala L Weir: Clinical and Health Informatics Research Group (Weir), Faculty of Medicine and Department of Epidemiology, Biostatistics and Occupational Health (Weir), McGill University, Montréal, Que.; Okaki Health Intelligence (Samanani), Calgary, Alta.; College of Physicians & Surgeons of Alberta (Gilani, Jess); School of Public Health (Eurich), University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes (Eurich), Edmonton, Alta.
  2. Salim Samanani: Clinical and Health Informatics Research Group (Weir), Faculty of Medicine and Department of Epidemiology, Biostatistics and Occupational Health (Weir), McGill University, Montréal, Que.; Okaki Health Intelligence (Samanani), Calgary, Alta.; College of Physicians & Surgeons of Alberta (Gilani, Jess); School of Public Health (Eurich), University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes (Eurich), Edmonton, Alta.
  3. Fizza Gilani: Clinical and Health Informatics Research Group (Weir), Faculty of Medicine and Department of Epidemiology, Biostatistics and Occupational Health (Weir), McGill University, Montréal, Que.; Okaki Health Intelligence (Samanani), Calgary, Alta.; College of Physicians & Surgeons of Alberta (Gilani, Jess); School of Public Health (Eurich), University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes (Eurich), Edmonton, Alta.
  4. Ed Jess: Clinical and Health Informatics Research Group (Weir), Faculty of Medicine and Department of Epidemiology, Biostatistics and Occupational Health (Weir), McGill University, Montréal, Que.; Okaki Health Intelligence (Samanani), Calgary, Alta.; College of Physicians & Surgeons of Alberta (Gilani, Jess); School of Public Health (Eurich), University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes (Eurich), Edmonton, Alta.
  5. Dean T Eurich: Clinical and Health Informatics Research Group (Weir), Faculty of Medicine and Department of Epidemiology, Biostatistics and Occupational Health (Weir), McGill University, Montréal, Que.; Okaki Health Intelligence (Samanani), Calgary, Alta.; College of Physicians & Surgeons of Alberta (Gilani, Jess); School of Public Health (Eurich), University of Alberta; Alliance for Canadian Health Outcomes Research in Diabetes (Eurich), Edmonton, Alta. deurich@ualberta.ca.
PMID: 30591546 DOI: 10.9778/cmajo.20180121

Abstract

BACKGROUND: There is increasing concern over the use of benzodiazepine receptor agonists (BZRAs). The objective of this study was to describe BZRA dispensations in the province of Alberta in 2015 according to age, sex and appropriateness.
METHODS: A population-based descriptive study of people 10 years of age or older with at least 1 BZRA dispensation in Alberta, Canada, between Jan. 1 and Dec. 31, 2015, was conducted. Prevalence of BZRA use, characteristics of BZRAs dispensations, use at the individual level and appropriateness were determined.
RESULTS: A total of 372 870 people received 2 463 585 BZRA dispensations in Alberta in 2015. Prevalence of use at the population level was 10% overall, increased with age ( value for trend < 0.001) and was consistently highest among females. Twenty percent of patients used both Z-drugs and benzodiazepines. BZRA users had an average of 7 dispensations (standard deviation [SD] 20), 137 days of use overall (SD 123) and a maximum period of consecutive use of 90 days (SD 95). Days of consecutive use were highest among those aged 65 years or older (126 d). A total of 62 795 (17%) people used more than 1 distinct BZRA ingredient concurrently and 10% had 3 or more distinct prescribers.
INTERPRETATION: The prevalence of BZRA use was high and a substantial proportion of use appeared to be potentially inappropriate. This study supports the need for continued monitoring for the prescribing and use of these medications at the population level.

References

  1. Pharmacoepidemiol Drug Saf. 2004 Oct;13(10):669-82 [PMID: 15386589]
  2. Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):455-63 [PMID: 15651088]
  3. J Clin Psychiatry. 2005;66 Suppl 2:28-33 [PMID: 15762817]
  4. Age Ageing. 2008 Nov;37(6):673-9 [PMID: 18829684]
  5. J Affect Disord. 2009 Oct;117 Suppl 1:S1-2 [PMID: 19682750]
  6. Health Policy. 2010 Oct;97(2-3):122-9 [PMID: 20413177]
  7. Drugs Aging. 2012 Oct;29(10):829-37 [PMID: 23044639]
  8. BMJ. 2014 Mar 19;348:g1996 [PMID: 24647164]
  9. JAMA Intern Med. 2014 Jun;174(6):890-8 [PMID: 24733354]
  10. JAMA Psychiatry. 2014 Sep;71(9):1006-14 [PMID: 25006837]
  11. BMC Psychiatry. 2014;14 Suppl 1:S1 [PMID: 25081580]
  12. BMJ. 2014 Sep 09;349:g5205 [PMID: 25208536]
  13. CMAJ Open. 2014 Oct 01;2(4):E208-16 [PMID: 25485245]
  14. CMAJ Open. 2014 Oct 01;2(4):E256-61 [PMID: 25485251]
  15. J Am Geriatr Soc. 2015 Mar;63(3):486-500 [PMID: 25752646]
  16. J Psychiatry Neurosci. 2015 May;40(3):E27-8 [PMID: 25903036]
  17. Yale J Biol Med. 2015 Sep 03;88(3):247-56 [PMID: 26339207]
  18. Clin Drug Investig. 2016 Jul;36(7):519-30 [PMID: 27056579]
  19. Psychiatr Serv. 2016 Sep 1;67(9):1012-8 [PMID: 27133727]
  20. Age Ageing. 2016 Jul;45(4):535-42 [PMID: 27151390]
  21. Health Rep. 2016 Sep 21;27(9):24-30 [PMID: 27655169]
  22. Eur J Clin Pharmacol. 2017 Aug;73(8):1001-1008 [PMID: 28435984]
  23. J Am Geriatr Soc. 2018 Jul;66(6):1180-1185 [PMID: 29430639]
  24. Can Fam Physician. 2018 May;64(5):339-351 [PMID: 29760253]
  25. Can Geriatr J. 2018 Sep 30;21(3):269-273 [PMID: 30271512]
  26. Drug Metab Rev. 1978;8(1):13-28 [PMID: 31269]
Journal Article
Article has an altmetric score of 4

Word Cloud

Created with Highcharts 10.0.0useBZRAdispensationsstudyAlberta2015agepeople1levelreceptorBZRAsappropriatenesspopulation-baseddescriptiveyearsolderPrevalencetotalpopulation10%overallhighestamonguseddaysSDconsecutivedistinctBACKGROUND:increasingconcernbenzodiazepineagonistsobjectivedescribeprovinceaccordingsexMETHODS:10leastdispensationCanadaJanDec31conductedcharacteristicsindividualdeterminedRESULTS:372870received2463585increasedvaluetrend<0001consistentlyfemalesTwentypercentpatientsZ-drugsbenzodiazepinesusersaverage7standarddeviation[SD]20137123maximumperiod9095Daysaged65126d6279517%ingredientconcurrently3prescribersINTERPRETATION:prevalencehighsubstantialproportionappearedpotentiallyinappropriatesupportsneedcontinuedmonitoringprescribingmedicationsBenzodiazepineagonistAlberta:

Similar Articles

Cited By (3)